Published in Blood on November 07, 2002
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A (2010) 1.72
HIF1alpha synergizes with glucocorticoids to promote BFU-E progenitor self-renewal. Blood (2010) 1.63
Mechanism of human Hb switching: a possible role of the kit receptor/miR 221-222 complex. Haematologica (2010) 0.91
MicroRNAs: Allies or foes in erythropoiesis? J Cell Physiol (2012) 0.81
Differentiation potential of o bombay human-induced pluripotent stem cells and human embryonic stem cells into fetal erythroid-like cells. Cell J (2015) 0.75
Role of stem cell factor in the reactivation of human fetal hemoglobin. Mediterr J Hematol Infect Dis (2009) 0.75
Identification and expansion of human colon-cancer-initiating cells. Nature (2006) 24.44
MicroRNA-133 controls cardiac hypertrophy. Nat Med (2007) 11.68
The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med (2008) 5.74
MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A (2005) 5.54
MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nat Cell Biol (2007) 4.02
Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One (2008) 3.68
The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res (2008) 3.21
Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol (2008) 2.56
Relation of various plasma growth factor levels in patients with stable angina pectoris and total occlusion of a coronary artery to the degree of coronary collaterals. Am J Cardiol (2005) 2.14
A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol (2008) 1.97
Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Exp Hematol (2008) 1.68
Triterpenoids as new promising anticancer drugs. Anticancer Drugs (2009) 1.60
Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina. Am Heart J (2006) 1.59
The emerging role of MIR-146A in the control of hematopoiesis, immune function and cancer. J Hematol Oncol (2012) 1.56
TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. J Cell Sci (2006) 1.55
Expression of alternative transcripts of ferroportin-1 during human erythroid differentiation. Haematologica (2005) 1.53
CDDO-Im is a stimulator of megakaryocytic differentiation. Leuk Res (2010) 1.42
Identification of the hemangioblast in postnatal life. Blood (2002) 1.42
MicroRNA 223-dependent expression of LMO2 regulates normal erythropoiesis. Haematologica (2009) 1.40
Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death. J Exp Med (2004) 1.38
The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis (2010) 1.34
Human fetal aorta contains vascular progenitor cells capable of inducing vasculogenesis, angiogenesis, and myogenesis in vitro and in a murine model of peripheral ischemia. Am J Pathol (2007) 1.31
Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood (2002) 1.30
Transplantation of low dose CD34+KDR+ cells promotes vascular and muscular regeneration in ischemic limbs. FASEB J (2004) 1.27
Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood (2002) 1.25
Homologous transplantation of neural stem cells to the injured spinal cord of mice. Neurosurgery (2005) 1.22
MicroRNA 155 modulates megakaryopoiesis at progenitor and precursor level by targeting Ets-1 and Meis1 transcription factors. Br J Haematol (2008) 1.22
Regulation of cell size and contractile function by AKT in cardiomyocytes. Ann N Y Acad Sci (2004) 1.19
TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica (2005) 1.19
IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol (2004) 1.18
Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res (2009) 1.17
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood (2008) 1.16
Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res (2005) 1.15
CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. Eur J Immunol (2004) 1.15
Correlations between progression of coronary artery disease and circulating endothelial progenitor cells. FASEB J (2010) 1.10
Heart infarct in NOD-SCID mice: therapeutic vasculogenesis by transplantation of human CD34+ cells and low dose CD34+KDR+ cells. FASEB J (2004) 1.09
Role of PLZF in melanoma progression. Oncogene (2004) 1.07
Multiple members of the TNF superfamily contribute to IFN-gamma-mediated inhibition of erythropoiesis. J Immunol (2005) 1.05
Thyroid hormone receptor TRbeta1 mediates Akt activation by T3 in pancreatic beta cells. J Mol Endocrinol (2007) 1.05
NFI-A directs the fate of hematopoietic progenitors to the erythroid or granulocytic lineage and controls beta-globin and G-CSF receptor expression. Blood (2009) 1.05
Inhibition of TPO-induced MEK or mTOR activity induces opposite effects on the ploidy of human differentiating megakaryocytes. J Cell Sci (2006) 1.04
Podocalyxin is expressed in normal and leukemic monocytes. Blood Cells Mol Dis (2006) 1.03
PLZF induces megakaryocytic development, activates Tpo receptor expression and interacts with GATA1 protein. Oncogene (2002) 0.98
Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol Dis (2007) 0.98
Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis (2007) 0.97
A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol Oncol (2007) 0.96
Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer Res (2007) 0.96
MicroRNAs in normal and malignant myelopoiesis. Leuk Res (2009) 0.94
Methylation damage response in hematopoietic progenitor cells. DNA Repair (Amst) (2007) 0.93
Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells. Blood (2005) 0.93
Bone marrow-derived progenitors are greatly reduced in patients with severe COPD and low-BMI. Respir Physiol Neurobiol (2009) 0.92
MicroRNA-486-3p regulates γ-globin expression in human erythroid cells by directly modulating BCL11A. PLoS One (2013) 0.92
Mechanism of human Hb switching: a possible role of the kit receptor/miR 221-222 complex. Haematologica (2010) 0.91